Prospective Grant of Exclusive License: Biomarkers for Acute Ischemic Stroke, 28633-28634 [2015-12005]

Download as PDF Federal Register / Vol. 80, No. 96 / Tuesday, May 19, 2015 / Notices and Research Supports Awards, National Institutes of Health, HHS) Dated: May 13, 2015. Melanie J. Gray-Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–12012 Filed 5–18–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meetings tkelley on DSK3SPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Inflammation and AD. Date: June 18, 2015. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: DoubleTree Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Alexander Parsadanian, Ph.D., Scientific Review Officer, National Institute on Aging, Gateway Building 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9666, PARSADANIANA@ NIA.NIH.GOV. Name of Committee: National Institute on Aging Special Emphasis Panel; Epigenetic RFA. Date: June 23, 2015. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, Suite 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: BITA NAKHAI, Ph.D., SCIENTIFIC REVIEW BRANCH, NATIONAL INSTITUTE ON AGING, GATEWAY BLDG., 2C212, 7201 WISCONSIN AVENUE, Bethesda, MD 20814, 301–402–7701, nakhaib@nia.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel, Vascular Contributions to AD. Date: June 29, 2015. Time: 8:00 a.m. to 4:00 p.m. VerDate Sep<11>2014 18:13 May 18, 2015 Jkt 235001 28633 Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, Bethesda, MD 20814. Contact Person: Alexander Parsadanian, Ph.D., Scientific Review Officer, National Institute on Aging, Gateway Building 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–496–9666, PARSADANIANA@ NIA.NIH.GOV. Name of Committee: National Institute on Aging Special Emphasis Panel, Novel Molecular Mechanism of Longevity. Date: July 15, 2015. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, Suite 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Bita Nakhai, Ph.D., Scientific Review Branch, National Institute on Aging, Gateway Bldg., 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20814, 301–402–7701, nakhaib@nia.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Place: National Institutes of Health, Room 4F100, 5601 Fishers Lane, Rockville, MD 20892. Time: June 19, 2015, 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Room 4F100, 5601 Fishers Lane, Rockville, MD 20892. Contact Person: Maja Maric, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3F21A, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Rockville, MD 20852, (240) 669–5025, maja.maric@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: May 13, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2015–12013 Filed 5–18–15; 8:45 am] BILLING CODE 4140–01–P Dated: May 13, 2015. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–12006 Filed 5–18–15; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health Prospective Grant of Exclusive License: Biomarkers for Acute Ischemic Stroke DEPARTMENT OF HEALTH AND HUMAN SERVICES AGENCY: National Institutes of Health ACTION: National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting SUMMARY: Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Investigator Initiated Program Project Applications. Time: June 11, 2015, 9:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 National Institutes of Health, HHS. Notice. This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license, to practice the inventions embodied in the following patent applications: 1. U.S. Provisional Patent Application No. 61/307,233, filed 23 February 2010 HHS Ref. No.: E–023–2010/0–US–01 Titled: Biomarkers for Acute Ischemic Stroke 2. PCT Patent Application No. PCT/ US2011/025748, filed 22 February 2011 HHS Ref. No.: E–023–2010/0–PCT–02 Titled: Biomarkers for Acute Ischemic Stroke 3. U.S. Patent Application No. 13/ 580,571, filed 22 August 2012 HHS Ref. No.: E–023–2010/0–US–03 Titled: Biomarkers for Acute Ischemic Stroke to VuEssence, Inc., a company incorporated under the laws of the State of Florida having its headquarters in E:\FR\FM\19MYN1.SGM 19MYN1 tkelley on DSK3SPTVN1PROD with NOTICES 28634 Federal Register / Vol. 80, No. 96 / Tuesday, May 19, 2015 / Notices Odessa, Florida. The patent rights in these inventions have been assigned to the United States of America. DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before June 18, 2015 will be considered. ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Jaime M. Greene, M.S., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5559; Email: greenejaime@mail.nih.gov; Facsimile: (301) 402–0220. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization. SUPPLEMENTARY INFORMATION: This technology is directed to gene biomarkers for the diagnosis and potential treatment of acute ischemic stroke. Stroke is the third leading cause of death in the United States, of which 87% are ischemic stroke and result in death within 30 days in 8–12% of the cases. Currently, recombinant tissue plasminogen activator (rtPA, trade name alteplase), is the only FDA approved ischemic stroke treatment, and it is only effective when administered to patients within three hours from the onset of symptoms. Unfortunately, the median time from stroke symptom onset to presentation to the emergency department is 3–6 hours. Although advances in neuroimaging and clinical management have helped with patient survival rates, these techniques are not infallible and at times result in misdiagnosis. The biomarkers identified in this technology may be used to develop a diagnostic testing device for determining stroke subtype in the field. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless, within thirty (30) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments VerDate Sep<11>2014 16:53 May 18, 2015 Jkt 235001 and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: May 12, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2015–12005 Filed 5–18–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Topics in Gastroenterology. Date: June 10, 2015. Time: 2:00 p.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Jonathan K. Ivins, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040A, MSC 7806, Bethesda, MD 20892, (301) 594– 1245, ivinsj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; NRCS Palliative Care and Survivorship. Date: June 11, 2015. Time: 11:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Long Beach Hotel, 111 East Ocean Blvd., Long Beach, CA 90802. Contact Person: Martha L. Hare, Ph.D., RN, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3154, Bethesda, MD 20892, (301) 451–8504, harem@mail.nih.gov. Name of Committee: Bioengineering Sciences & Technologies Integrated Review PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Group; Biomaterials and Biointerfaces Study Section. Date: June 17–18, 2015. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Admiral Fell Inn, 888 South Broadway, Baltimore, MD 21231. Contact Person: Joseph D. Mosca, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5158, MSC 7808, Bethesda, MD 20892, (301) 408– 9465, moscajos@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; BD2K: Biomedical Data Science Training Coordination Center. Date: June 17, 2015. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Luis Espinoza, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4140, MSC 7814, Bethesda, MD 20892, 301–435– 0952, espinozala@mail.nih.gov. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Electrical Signaling, Ion Transport, and Arrhythmias Study Section. Date: June 18, 2015. Time: 7:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington Embassy Row, 2015 Massachusetts Ave. NW., Washington, DC 20036. Contact Person: Yuanna Cheng, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7814, Bethesda, MD 20892, (301) 435– 1195, Chengy5@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Electrical Signaling, Ion Transport and Arrhythmias Special Panel. Date: June 18, 2015. Time: 7:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Pier 5 Hotel, 711 Eastern Avenue, Baltimore, MD 21202. Contact Person: Lawrence E. Boerboom, Ph.D., Chief, CVRS IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4130, MSC 7814, Bethesda, MD 20892, (301) 435–8367, boerboom@nih.gov. Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Gene and Drug Delivery Systems Study Section. Date: June 18–19, 2015. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814. E:\FR\FM\19MYN1.SGM 19MYN1

Agencies

[Federal Register Volume 80, Number 96 (Tuesday, May 19, 2015)]
[Notices]
[Pages 28633-28634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-12005]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Biomarkers for Acute 
Ischemic Stroke

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
404, that the National Institutes of Health (NIH), Department of Health 
and Human Services (HHS), is contemplating the grant of an exclusive 
license, to practice the inventions embodied in the following patent 
applications:

1. U.S. Provisional Patent Application No. 61/307,233, filed 23 
February 2010
    HHS Ref. No.: E-023-2010/0-US-01
    Titled: Biomarkers for Acute Ischemic Stroke
2. PCT Patent Application No. PCT/US2011/025748, filed 22 February 2011
    HHS Ref. No.: E-023-2010/0-PCT-02
    Titled: Biomarkers for Acute Ischemic Stroke
3. U.S. Patent Application No. 13/580,571, filed 22 August 2012
    HHS Ref. No.: E-023-2010/0-US-03
    Titled: Biomarkers for Acute Ischemic Stroke

to VuEssence, Inc., a company incorporated under the laws of the State 
of Florida having its headquarters in

[[Page 28634]]

Odessa, Florida. The patent rights in these inventions have been 
assigned to the United States of America.

DATES: Only written comments and/or applications for a license received 
by the NIH Office of Technology Transfer on or before June 18, 2015 
will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Jaime M. Greene, M.S., Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-5559; Email: 
greenejaime@mail.nih.gov; Facsimile: (301) 402-0220. A signed 
confidentiality nondisclosure agreement will be required to receive 
copies of any patent applications that have not been published or 
issued by the United States Patent and Trademark Office or the World 
Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology is directed to gene 
biomarkers for the diagnosis and potential treatment of acute ischemic 
stroke. Stroke is the third leading cause of death in the United 
States, of which 87% are ischemic stroke and result in death within 30 
days in 8-12% of the cases. Currently, recombinant tissue plasminogen 
activator (rtPA, trade name alteplase), is the only FDA approved 
ischemic stroke treatment, and it is only effective when administered 
to patients within three hours from the onset of symptoms. 
Unfortunately, the median time from stroke symptom onset to 
presentation to the emergency department is 3-6 hours. Although 
advances in neuroimaging and clinical management have helped with 
patient survival rates, these techniques are not infallible and at 
times result in misdiagnosis. The biomarkers identified in this 
technology may be used to develop a diagnostic testing device for 
determining stroke subtype in the field.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive license may be granted unless, within 
thirty (30) days from the date of this published notice, NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR part 404.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: May 12, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-12005 Filed 5-18-15; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.